This is a preview of subscription content, log in via an institution to check access.
Reference
Li N, et al. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China. Clinical Drug Investigation : 13 Oct 2017. Available from: URL: http://doi.org/10.1007/s40261-017-0587-z
Rights and permissions
About this article
Cite this article
Imatinib good choice for CML-CP in China. PharmacoEcon Outcomes News 790, 17 (2017). https://doi.org/10.1007/s40274-017-4462-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4462-1